A novel process for the preparation of lapatinib and its pharmaceutically acceptable salts
作者： Bhujanga rao Adibhatla Kali Satya , Ramanadham Jyothi Prasad , Nannapaneni Venkaiah Chowdary
DOI:
关键词: Lapatinib 、 Materials science 、 Combinatorial chemistry 、 Base (group theory) 、 Stereochemistry
摘要: The present invention relates to an improved and novel process for the preparation of high purity crystalline base Lapatinib formula-(l) having chemical name N-{3-chloro-4-[(3- fluorobenzyloxy]phenyl}-6-[5-({[2-(methanesuIfonyl) ethyl]amino}methyl]-2-furyl]-4-quin - azolinamine its pharmaceutically acceptable salts. further intermediates according formula (8) (9) used in this
google.it 参考文章(12)
Matthew James Welham, John Peter Gilday, Process for the manufacture of gefitinib ,(2004)
NV Harris, C Smith, K Bowden, Antifolate and antibacterial activities of 6-substituted 2,4-diaminoquinazolines European Journal of Medicinal Chemistry. ,vol. 27, pp. 7- 18 ,(1992) , 10.1016/0223-5234(92)90054-5
Wenle Xia, Catherine M Gerard, Leihua Liu, Nathalie M Baudson, Thierry L Ory, Neil L Spector, Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells Oncogene. ,vol. 24, pp. 6213- 6221 ,(2005) , 10.1038/SJ.ONC.1208774
Wenle Xia, Robert J Mullin, Barry R Keith, Lei-Hua Liu, Hong Ma, David W Rusnak, Gary Owens, Krystal J Alligood, Neil L Spector, Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways Oncogene. ,vol. 21, pp. 6255- 6263 ,(2002) , 10.1038/SJ.ONC.1205794
George Stuart GlaxoSmithKline Cockerill, Karen Elizabeth Glaxosmithkline Lackey, Kathryn Jane Glaxosmithkline Smith, Stephen Barry Glaxosmithkline Guntrip, Malcolm Clive GlaxoSmithKline Carter, Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors ,(1997)
Neil L. Spector, Wenle Xia, Howard Burris, Herbert Hurwitz, E. Claire Dees, Afshin Dowlati, Bert O'Neil, Beth Overmoyer, Paul K. Marcom, Kimberly L. Blackwell, Deborah A. Smith, Kevin M. Koch, Andrew Stead, Steven Mangum, Matthew J. Ellis, Leihua Liu, Albert K. Man, Troy M. Bremer, Jennifer Harris, Sarah Bacus, Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies Journal of Clinical Oncology. ,vol. 23, pp. 2502- 2512 ,(2005) , 10.1200/JCO.2005.12.157
Frank Glaxosmithkline Roschangar, Mark J. Glaxosmithkline Sacchetti, Martin H. Glaxosmithkline Osterhout, Michael S. Glaxosmithkline Mcclure, Quinazoline ditosylate salt compounds ,(2001)
Howard A. Burris, Herbert I. Hurwitz, E. Claire Dees, Afshin Dowlati, Kimberly L. Blackwell, Bert O'Neil, Paul K. Marcom, Matthew J. Ellis, Beth Overmoyer, Suzanne F. Jones, Jennifer L. Harris, Deborah A. Smith, Kevin M. Koch, Andrew Stead, Steve Mangum, Neil L. Spector, Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas Journal of Clinical Oncology. ,vol. 23, pp. 5305- 5313 ,(2005) , 10.1200/JCO.2005.16.584
Leonid Metsger, Noa Kipnis, Sofia Gorohovsky-Rosenberg, Dikla Lavy, Slavik Yurkovski, Lapatinib, salts thereof, processes and intermediates for their preparation ,(2009)
Chana Surinder, QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ,(2008)